Related Experiment Video

Updated: Sep 22, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.0K

Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes

Angeliki Bourazana1, Grigorios Giamouzis1, John Skoularigis1

  • 1Department of Cardiology, University Hospital of Larissa, Larissa 41110, Greece.

World Journal of Cardiology
|May 18, 2022
PubMed

Insights

Dipeptidyl peptidase-4 (DPP-4) inhibitors effectively manage blood glucose in type 2 diabetes. However, studies show these drugs have a neutral effect on major cardiovascular outcomes in diabetic patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus (DM) is linked to diverse heart failure phenotypes, including structural and electrical cardiac remodeling.
  • Diabetic cardiomyopathy presents a spectrum from subclinical abnormalities to severe biventricular dysfunction and increased mortality.
  • Type 2 DM affects millions globally, necessitating effective management strategies for both glycemic control and cardiovascular health.

Purpose of the Study:

  • To evaluate the cardiovascular outcomes of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes.
  • To assess the impact of DPP-4 inhibitors on myocardial infarction, stroke, heart failure hospitalizations, and cardiovascular death.
  • To investigate the potential association between DPP-4 inhibitor use and atrial flutter in diabetic patients.

Main Methods:

  • Review of clinical data and studies investigating DPP-4 inhibitors in type 2 diabetes.
  • Analysis of cardiovascular event rates, including myocardial infarction, stroke, and heart failure hospitalizations.
  • Exploration of cardiac electrical remodeling and potential links to atrial flutter in the context of DPP-4 inhibitor therapy.

Main Results:

  • DPP-4 inhibitors demonstrate efficacy in lowering blood glucose levels by enhancing incretin hormone activity.
  • The cardiovascular outcomes associated with DPP-4 inhibitor use in diabetic patients have been found to be neutral.
  • No significant impact was observed on major adverse cardiovascular events such as myocardial infarction, stroke, or cardiovascular death.

Conclusions:

  • DPP-4 inhibitors are a safe and effective glucose-lowering option for type 2 diabetes, but do not confer cardiovascular benefits.
  • Further research is warranted to explore the relationship between DPP-4 inhibitors and atrial flutter in the diabetic population.
  • While managing hyperglycemia, DPP-4 inhibitors do not appear to alter the cardiovascular risk profile in patients with diabetes.

Keywords:
Atrial flutterDiabetes mellitusDipeptidyl peptidase-4 inhibitorsHeart failureMeta-analysisOutcomes

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

388
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.9K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
315
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
420
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
288
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K